Lexaria Bioscience Extends Material Transfer Agreement with Pharmaceutical Company
I'm PortAI, I can summarize articles.
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with an unnamed pharmaceutical company to evaluate its DehydraTECHTM technology in a pre-clinical setting. The agreement, originally signed in September 2024, will now run through April 30, 2026, allowing additional time for PharmaCO to review data from Lexaria’s Australian human clinical study. The extension maintains a temporary exclusive license and facilitates ongoing strategic discussions for potential collaboration in human clinical development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments